PMID- 36292242
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221030
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 12
IP  - 10
DP  - 2022 Oct 20
TI  - Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism Induced 
      by Multiple Endocrine Neoplasia 1-A Case Report.
LID - 10.3390/diagnostics12102553 [doi]
LID - 2553
AB  - Multiple endocrine neoplasia type 1 (MEN1) is a syndrome characterized by the 
      occurrence of two or more endocrine gland tumors. Here, we show a case of a 
      52-year-old man diagnosed with MEN1 through gastrinoma, parathyroid adenoma and 
      gene detection. The MEN1 patient's case was complicated with relapsed primary 
      hyperparathyroidism (PHPT), and they received ultrasound-guided radiofrequency 
      ablation (RFA). The patient had a remarkable recovery after RFA treatment for the 
      relapsed PHPT. It might be an alternative treatment for MEN1 patients with poor 
      conditions such as high surgical risk, unwillingness to choose parathyroid 
      surgery or those unable to tolerate surgery. Individualized therapy significantly 
      benefits the prognosis of MEN1 patients.
FAU - Han, Zhenping
AU  - Han Z
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
AD  - Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou 310014, China.
FAU - Li, Tingting
AU  - Li T
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
FAU - Wang, Siyi
AU  - Wang S
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
AD  - Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang 
      University of Technology, Hangzhou 310014, China.
FAU - Gao, Li
AU  - Gao L
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
FAU - Hu, Ying
AU  - Hu Y
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
AD  - Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou 310014, 
      China.
FAU - Zhao, Yu
AU  - Zhao Y
AD  - Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou 310014, 
      China.
AD  - Department of Endocrinology, Zhejiang Provincial People's Hospital, Affiliated 
      People's Hospital, Hangzhou Medical College, Hangzhou 310014, China.
FAU - Yan, Jieping
AU  - Yan J
AD  - Center for Clinical Pharmacy, Department of Pharmacy, Zhejiang Provincial 
      People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, 
      Hangzhou 310014, China.
AD  - Key Laboratory of Endocrine Gland Diseases of Zhejiang Province, Hangzhou 310014, 
      China.
LA  - eng
GR  - 81903597/National Natural Science Foundation of China/
GR  - LQ16H310003/Zhejiang Provincial Natural Science Foundation/
GR  - 2021KY016/Medical and Health Science and Technology Research Program of Zhejiang 
      Province/
GR  - 2021KY018/Medical and Health Science and Technology Research Program of Zhejiang 
      Province/
GR  - 2019RC096/Medical and Health Science and Technology Research Program of Zhejiang 
      Province/
PT  - Journal Article
DEP - 20221020
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC9600646
OTO - NOTNLM
OT  - multiple endocrine neoplasia type 1
OT  - parathyroid
OT  - primary hyperparathyroidism
OT  - radiofrequency ablation
OT  - ultrasound-guided
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/28 06:00
MHDA- 2022/10/28 06:01
PMCR- 2022/10/20
CRDT- 2022/10/27 01:17
PHST- 2022/09/15 00:00 [received]
PHST- 2022/10/13 00:00 [revised]
PHST- 2022/10/19 00:00 [accepted]
PHST- 2022/10/27 01:17 [entrez]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/28 06:01 [medline]
PHST- 2022/10/20 00:00 [pmc-release]
AID - diagnostics12102553 [pii]
AID - diagnostics-12-02553 [pii]
AID - 10.3390/diagnostics12102553 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2022 Oct 20;12(10):2553. doi: 10.3390/diagnostics12102553.